These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 9374685)

  • 1. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
    Drewes C; Nauck MA; Horn R; Holst J; Schmiegel W; Brabant G
    Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
    Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
    Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.
    Chelikani PK; Haver AC; Reidelberger RD
    Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1695-706. PubMed ID: 15718384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.
    Qualmann C; Nauck MA; Holst JJ; Orskov C; Creutzfeldt W
    Acta Diabetol; 1995 Mar; 32(1):13-6. PubMed ID: 7612912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
    Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
    Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
    Dupre J; Behme MT; Hramiak IM; McFarlane P; Williamson MP; Zabel P; McDonald TJ
    Diabetes; 1995 Jun; 44(6):626-30. PubMed ID: 7789625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
    Ritzel R; Orskov C; Holst JJ; Nauck MA
    Diabetologia; 1995 Jun; 38(6):720-5. PubMed ID: 7672496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
    Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
    Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
    Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
    Gutniak MK; Svartberg J; Hellström PM; Holst JJ; Adner N; Ahrén B
    J Intern Med; 2001 Jul; 250(1):81-7. PubMed ID: 11454146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.